Forte Biosciences, Inc.

NasdaqCM:FBRX Stock Report

Market Cap: US$22.8m

Forte Biosciences Past Earnings Performance

Past criteria checks 0/6

Forte Biosciences's earnings have been declining at an average annual rate of -3.9%, while the Biotechs industry saw earnings growing at 19.1% annually.

Key information

-3.9%

Earnings growth rate

58.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-365.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Revenue & Expenses Breakdown

How Forte Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:FBRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-341620
30 Jun 240-361720
31 Mar 240-321221
31 Dec 230-311122
30 Sep 230-301021
30 Jun 230-24816
31 Mar 230-18910
31 Dec 220-1486
30 Sep 220-1284
30 Jun 220-1789
31 Mar 220-19811
31 Dec 210-22814
30 Sep 210-23716
30 Jun 210-20614
31 Mar 210-49512
31 Dec 200-46410
30 Sep 200-4338
30 Jun 200-3925
31 Mar 200-523
31 Dec 190-413

Quality Earnings: FBRX is currently unprofitable.

Growing Profit Margin: FBRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FBRX is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare FBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: FBRX has a negative Return on Equity (-365.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies